Cancer charities have reacted with disappointment to news that a drug to treat advanced prostate cancer has not been deemed cost-effective for the NHS by health officials. Enzalutamide is currently available on the Cancer Drugs Fund in England, which enables patients to access drugs that would not otherwise have been routinely available from the NHS.